GlassScriptPhysician profile
Godfrey S Chithambo
NPI 1366470379
$5,185.93
in general payments reported to CMS, 2019-2025
42 companies · $1,304 in 2025
The $1,304 reported for 2025 was more than what 88% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $533 · 2020: $345 · 2021: $538 · 2022: $753 · 2023: $987 · 2024: $726 · 2025: $1,304.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,017.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,016.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $669.06 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $514.28 | 2021-2025 | Qulipta, Ubrelvy, Vraylar |
| Abbott Laboratories | $381.90 | 2023-2025 | Freestyle Libre 3 |
| Lilly USA, LLC | $362.50 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Astrazeneca Pharmaceuticals LP | $340.58 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Otsuka America Pharmaceutical, INC. | $321.62 | 2022-2025 | Rexulti |
| Pfizer INC. | $319.68 | 2019-2025 | |
| Amarin Pharma, INC. | $292.59 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $228.67 | 2019-2025 | |
| Glaxosmithkline, LLC. | $191.72 | 2020-2025 | Shingrix, Trelegy Ellipta, Arexvy |
| Merck Sharp & Dohme LLC | $168.81 | 2019-2025 | Gardasil 9, Capvaxive, Gardasil |
| Amgen INC. | $153.14 | 2019-2025 | Repatha, Otezla, Repatha |
| Astellas Pharma US INC | $139.86 | 2023-2025 | Veozah, Myrbetriq |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $139.64 | 2020-2023 | Xifaxan |
| Corcept Therapeutics | $122.27 | 2025 | Korlym |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Godfrey Chithambo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.